[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [Myeloid neoplasms](https://durgical.com/en/haematology/areas/myeloid/) › CML on tyrosine kinase inhibitors: response milestones and resistance

# CML on tyrosine kinase inhibitors: response milestones and resistance

- Treatment and support

A daily pill turned [chronic myeloid leukaemia](https://durgical.com/en/conditions/chronic-myeloid-leukaemia/) into a long-term condition, but only if it is taken every day and its effect is measured on schedule.

Updated Nov 15, 2026

## Key points

- PCR milestones: about 10% at 3 months, under 1% at 6 months, 0.1% (MMR) at 12 months.
- Missed milestone: adherence first, then interactions, then mutation testing.
- T315I: only [ponatinib](https://durgical.com/en/pharmacology/ponatinib/) and [asciminib](https://durgical.com/en/pharmacology/asciminib/) work.
- [Dasatinib](https://durgical.com/en/pharmacology/dasatinib/) = effusions; [nilotinib](https://durgical.com/en/pharmacology/nilotinib/) = QT, [glucose](https://durgical.com/en/biochemistry/molecules/glucose/), arteries; [imatinib](https://durgical.com/en/pharmacology/imatinib/) = swelling and cramps.
- Deep, sustained response: some patients can stop the TKI under close PCR monitoring.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Common traps
- Elsewhere in DurgiPedia

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections The TKIs side by side (generic names, no doses)
- Connections

## What it is

Chronic myeloid leukaemia (CML) is driven by the BCR::ABL1 fusion, a [tyrosine](https://durgical.com/en/biochemistry/molecules/tyrosine/) kinase that is always on. Tyrosine [kinase inhibitors](https://durgical.com/en/pharmacology/classes/kinase-inhibitors/) (TKIs) block it: imatinib (first generation), dasatinib, nilotinib and [bosutinib](https://durgical.com/en/pharmacology/bosutinib/) (second generation), ponatinib (third generation) and asciminib (which binds a different pocket of the kinase). Response is followed by quantitative PCR for BCR::ABL1 transcripts reported on the International Scale (IS), which lets results from different laboratories be compared.

## How to think about it

The PCR is a countdown in steps of ten. The leukaemia burden should fall by a factor of ten roughly every few months: about 10% at 3 months, about 1% by 6 months, 0.1% (major molecular response) by 12 months. Each milestone is a checkpoint. Missing one means check the driver first (is the pill being taken, and absorbed?), then the engine (has the kinase mutated?).

## What to know

- Milestones by principle: BCR::ABL1 at or below 10% IS at 3 months, below 1% by 6 months, at or below 0.1% (major molecular response, MMR) by 12 months; deeper responses are MR4 (0.01%) and MR4.5.
- A result above 10% at 6 months, above 1% at 12 months or later, or a new resistance mutation is treatment failure and needs action.
- The commonest cause of failure is not taking the drug every day; next come [drug interactions](https://durgical.com/en/pharmacology/topics/drug-interactions/), poor absorption and kinase domain mutations.
- The T315I mutation resists imatinib, dasatinib, nilotinib and bosutinib; ponatinib and asciminib remain active.
- Side effects differ by drug: imatinib, swelling and muscle cramps; dasatinib, [pleural effusions](https://durgical.com/en/conditions/pleural-effusion/) and [pulmonary hypertension](https://durgical.com/en/general-pathology/pulmonary-hypertension/); nilotinib, QT prolongation, high glucose and arterial narrowing; bosutinib, diarrhoea and [liver](https://durgical.com/en/anatomy/liver/) enzymes; ponatinib, arterial clots and high [blood pressure](https://durgical.com/en/physiology/systolic-diastolic-mean-and-pulse-pressure/).
- With a sustained deep response for several years, some patients can stop the TKI under close PCR monitoring (treatment-free remission); about half stay in remission, and most who relapse respond again when the drug is restarted.

## How it is done (and why)

- Confirm the diagnosis and phase: count, smear, marrow with cytogenetics, and baseline quantitative BCR::ABL1 PCR.
- Choose the TKI by the patient: other illnesses (heart, lungs, [pancreas](https://durgical.com/en/anatomy/pancreas/), diabetes), drug interactions, risk score and goals such as stopping later.
- Check the full count often in the first weeks: TKIs can lower counts while normal blood cells recover.
- Measure BCR::ABL1 by PCR (IS) every 3 months until MMR is reached, then every 3 to 6 months.
- Milestone missed: check adherence, interacting drugs and how the pill is taken, then test for kinase domain mutations.
- Change TKI according to the mutation and side effects; progression or multiple failures: consider allogeneic stem cell transplantation.
- Sustained deep response for years: discuss a supervised attempt to stop, with monthly PCR at first.

## The TKIs side by side (generic names, no doses)

| Drug | Generation and binding | Classic side effects to watch | Note |
| --- | --- | --- | --- |
| Imatinib | First; ATP pocket | Swelling around the eyes, [fluid retention](https://durgical.com/en/conditions/fluid-volume-overload/), muscle cramps, nausea | Longest experience; slower deep responses |
| Dasatinib | Second; ATP pocket | Pleural effusion, pulmonary hypertension, low platelets | Absorption falls with acid-suppressing drugs |
| Nilotinib | Second; ATP pocket | QT prolongation, high glucose and lipids, pancreatitis, arterial narrowing | Taken on an empty [stomach](https://durgical.com/en/anatomy/stomach/); ECG before and during |
| Bosutinib | Second; ATP pocket | Diarrhoea, raised liver enzymes | An option first line or when other TKIs are not tolerated |
| Ponatinib | Third; ATP pocket | Arterial occlusion, high blood pressure, liver toxicity | Active against T315I |
| Asciminib | Binds the myristoyl pocket (allosteric) | Low counts, raised [pancreatic enzymes](https://durgical.com/en/pharmacology/pancrelipase/) | Active against T315I |

## Risks and precautions

- TKIs are metabolised largely by [CYP3A4](https://durgical.com/en/biochemistry/enzymes/cytochrome-p450-3a4/): strong inhibitors (some [azole antifungals](https://durgical.com/en/pharmacology/classes/azole-antifungals/), [macrolides](https://durgical.com/en/pharmacology/classes/macrolides/), grapefruit) raise levels and inducers ([rifampicin](https://durgical.com/en/pharmacology/rifampicin/), some antiepileptics, [St John's wort](https://durgical.com/en/pharmacology/st-john-s-wort/)) lower them.
- TKIs can harm a fetus: pregnancy is planned with the haematologist, usually during a deep, stable response.
- Before nilotinib or dasatinib, assess the heart and lungs; in patients with vascular disease, the arterial risk of nilotinib and ponatinib weighs heavily.
- Taking a pill every day for years is hard: ask about missed doses kindly and often, and look for cost, side effects or depression as the reason.
- Accelerated or blast phase behaves like [acute leukaemia](https://durgical.com/en/conditions/acute-leukaemia/) and needs urgent specialist care, TKI plus chemotherapy and often transplantation.

## Monitoring and next step

- Quantitative BCR::ABL1 PCR on the International Scale every 3 months until MMR, then every 3 to 6 months; monthly in the first months after stopping a TKI.
- Full count every one to two weeks at the start, then less often once stable.
- Kinase domain mutation testing when a milestone is missed, a response is lost or the disease progresses.
- Drug-specific checks: ECG for QT with nilotinib, glucose and lipids with nilotinib, chest imaging if breathless on dasatinib, liver tests and blood pressure for all.
- A rising PCR in a patient who has been well: first ask about adherence and new medicines, then repeat the PCR.

## Common traps

- **Testing for mutations before asking about adherence**: missed pills are the commonest reason a milestone is missed.
- **Comparing PCR results off the International Scale, or across laboratories without standardisation**: such results are not comparable.
- **Switching from one ATP-pocket TKI to another in a T315I mutation**: only ponatinib or asciminib work.
- **Starting a strong CYP3A4 inhibitor or an acid suppressant on a TKI**: check the interaction first.
- **Stopping a TKI outside a monitored programme**: relapse may be missed until it is no longer a quiet molecular one.

## Test yourself

Think of the answer, then tap the question to see it.

## At 12 months on imatinib, BCR::ABL1 is 2% IS. What should be checked first, before changing the drug?

Whether the patient takes the pill every day and any interacting drugs; then kinase domain mutation testing, and switching to another TKI.

## Why does a patient with the T315I mutation not respond to switching from imatinib to dasatinib?

T315I blocks binding of all first- and second-generation ATP-pocket TKIs; ponatinib or asciminib (binding another pocket) are needed.

## Which TKI would you avoid in a patient with recurrent pleural effusions, and why?

Dasatinib, because fluid around the lungs (pleural effusion) is its typical side effect.

## Why must PCR results be reported on the International Scale?

It standardises results between laboratories against a common baseline, so milestones such as 10%, 1% and 0.1% mean the same everywhere.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/cml-on-tyrosine-kinase-inhibitors-response-milestones-and-resistance/)

## Elsewhere in DurgiPedia

- [Chronic myeloid leukaemia](https://durgical.com/en/general-pathology/chronic-myeloid-leukaemia/)
- [Receptor tyrosine kinases](https://durgical.com/en/biochemistry/topics/receptor-tyrosine-kinases/)
- [Myeloproliferative neoplasms: overview](https://durgical.com/en/general-pathology/myeloproliferative-neoplasms-overview/)

## Connections

## Related 6

- [Chronic leukaemias: CML versus CLL (and hairy cell leukaemia)](https://durgical.com/en/haematology/chronic-leukaemias-cml-versus-cll/)
- [Myeloproliferative neoplasms and myelodysplasia: too much or made badly](https://durgical.com/en/haematology/myeloproliferative-neoplasms-and-myelodysplasia-too-much-or-made-badly/)
- [Stem cell transplantation: autologous or allogeneic, and what can go wrong](https://durgical.com/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/)
- [A high or low white count: which cell, and is it mature?](https://durgical.com/en/haematology/a-high-or-low-white-count-which-cell-and-is-it-mature/)
- [Marrow aspirate and biopsy, flow cytometry and genetics: which test answers which question](https://durgical.com/en/haematology/marrow-aspirate-and-biopsy-flow-cytometry-and-genetics-which-test-answers-which/)
- [How leukaemia is treated: induction, consolidation, targeted drugs and support](https://durgical.com/en/haematology/how-leukaemia-is-treated-induction-consolidation-targeted-drugs-and-support/)

## Related conditions 1

- [Chronic myeloid leukaemia](https://durgical.com/en/conditions/chronic-myeloid-leukaemia/)

## In Pharmacology 6

- [Imatinib](https://durgical.com/en/pharmacology/imatinib/)
- [Dasatinib](https://durgical.com/en/pharmacology/dasatinib/)
- [Nilotinib](https://durgical.com/en/pharmacology/nilotinib/)
- [Bosutinib](https://durgical.com/en/pharmacology/bosutinib/)
- [Ponatinib](https://durgical.com/en/pharmacology/ponatinib/)
- [Asciminib](https://durgical.com/en/pharmacology/asciminib/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version](https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq) (National Cancer Institute (NCI), 2026); [Chronic myelogenous leukemia (CML)](https://medlineplus.gov/ency/article/000570.htm) (MedlinePlus, US National Library of Medicine, 2024); [Imatinib: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a606018.html) (MedlinePlus (U.S. National Library of Medicine), 2025); [Chronic myeloid leukemia: MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/chronic-myeloid-leukemia/) (MedlinePlus, US National Library of Medicine, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/cml-on-tyrosine-kinase-inhibitors-response-milestones-and-resistance/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/cml-on-tyrosine-kinase-inhibitors-response-milestones-and-resistance/
